- About
- Projects
- Research
- Addressing Unmet Need Within the Animal and Veterinary Industries
- Antimicrobial Use Data in Food Animals
- Expanded Access Navigator
- Fellowship
- Food & Nutrition
- FDA Operational Evaluation
- FDA Patient Listening Sessions
- Improving Access to Publicly Available FDA Information
- Improving Understanding of the FDA and FDA-Regulated Products
- Substance Use Disorders
- COVID-19 Hub
- Regulatory Science Accelerator
- News and Events
- eRequest
Coverage
By December of 2023, a reorganization package based in part on the findings and recommendations of the Reagan-Udall Foundation's evaluation of the agency's infant formula response, and feedback from external and internal stakeholders, was completed.
We want to see the FDA use this momentum to keep focus on its core mission of food safety, make the cultural changes called for in the Reagan Udall Foundation’s report, and send a distinct signal that a strong, federal agency is protecting the health…
The Reagan-Udall Foundation for the FDA is leading an initiative to identify holistic approaches to address opportunities and challenges in animal health and veterinary medicine.
In establishing the Hub, FDA gathered feedback from stakeholders through a public meeting, held on Oct. 16, 2024 in collaboration with the Reagan-Udall Foundation.
In collaboration with the Reagan-Udall Foundation for the FDA, we hosted a public meeting, Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub, on October 16, 2024.
Federal agencies recently convened in a pivotal public meeting, hosted by the Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA), to discuss emerging treatments for post-traumatic stress disorder (PTSD), with a focus on the…
The reorganization had its origins in the Reagan-Udall Foundation report, which was released less than two years ago. The report focused on ways to clarify the mission of the human food program and achieve more urgency in preventing foodborne illnesses.
The oncology quality, characterization, and assessment of real-world data (Oncology QCARD) Initiative was formed to develop a set of minimum study design and data elements needed to evaluate the fitness of the real-world data (RWD) source(s) proposed in…
The rare disease policy calendar in Washington has been packed. Highlights have included an advisory committee meeting for a Barth syndrome treatment from Stealth BioTherapeutics, a meeting about FDA’s Rare Disease Innovation Hub convened by the Reagan-…
Advancing real-world data research through the Innovation in Medical Evidence and Development Surveillance (IMEDS) program: an interview with Carla Rodriguez-Watson, Reagan-Udall Foundation for the FDA.